BYANNLI 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification
Decision 
Information 
1 issued on 
Issued 2 / 
affected 3  
WS/2405 
This was an application for a variation following a 
25/05/2023 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
amended 
on 
SmPC, 
Labelling and 
PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
data 
PSUSA/2266/
Periodic Safety Update EU Single assessment - 
10/02/2022 
n/a 
PRAC Recommendation - maintenance 
202106 
paliperidone 
X/0002/G 
This was an application for a group of variations. 
16/09/2021 
22/11/2021 
SmPC, 
Labelling and 
PL 
Annex I_2.(c) Change or addition of a new 
strength/potency 
A.2.a - Administrative change - Change in the 
(invented) name of the medicinal product for CAPs 
C.I.7.b - Deletion of - a strength 
C.I.7.b - Deletion of - a strength 
C.I.7.b - Deletion of - a strength 
C.I.7.b - Deletion of - a strength 
C.I.7.b - Deletion of - a strength 
C.I.7.b - Deletion of - a strength 
A.7 - Administrative change - Deletion of 
manufacturing sites 
WS/1877 
This was an application for a variation following a 
09/04/2021 
22/11/2021 
SmPC and PL 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
Page 2/2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
